N = 25 COVID-19 patients with severe and/or life-threatening disease  Intervention group: patients receiving anti-inflammatory treatment (including tocilizumab and steroids) and anti-viral drugs, in addition to CP transfusion at median of 10 days' post symptom onset (n = 25)  No control group. Here, CP is linked to COVID-19.